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Abstract
Introduction. One of the methods of treating the limbs ischaemia is local intravascular fibrinolysis. The aim 
of using this method is fast restoration of arteries patency what enables blood flow to the ischaemic limb and 
allows to diagnose the cause of the occlusion of arteries or a vascular bypass. Identification and determination of 
the changes type in the arterial wall allows to plan further treatment using surgical and endovascular methods.
Material and methods. During 2003–2014, 41 patients were treated using the method of local fibrinolysis. 
In all of the cases the occlusion occurred in the femoropopliteal section. All of the patients had the colour Dop-
pler echocardiography carried out, and then angiography, to confirm the diagnosis. The catheter was inserted 
through a puncture in the common femoral artery. The catheter tip was placed above the arterial thrombus. In 
2003–2005 streptokinase was used as the fibrinolytic drug. Then, in 2005–2014 the usage of rtPA (alteplase) 
had been started. The progress of thrombolysis was monitored by repeated angiography. The fibrinolytic treatment 
had been continued for 6 more hours from obtaining the vessel patency confirmed by radiology.
Results. In 15 patients (88%) in 2003–2005 (group in which streptokinase was used) and 21 patients 
(87.5%) in 2005–2014 (group in which alteplase was used) patency of the initially clotted artery and full 
remission of the ischaemic limb symptoms was obtained. In 4 cases the intravascular thrombolysis ended with 
failure. Simultaneously, embolectomy with Fogarty’s catheter was carried out. In the group treated with rtPA 
two deaths were noted: due to acute coronary syndrome and hypertensive crisis.
Conclusions. Local intravascular fibrinolysis is a good and effective method of treatment of the limbs ischae-
mia in certain patients. It allows to lower the dosages of the thrombolytic drugs and can be a good alternative 
for the surgical treatment.
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Introduction
Today, local intravascular fibrinolysis is one of recog-
nised and little invasive techniques of endovasculari-
zation. It was used and described for the first time by 
Dotter in 1974 [1]. For 40 years the fibrinolytic factor 
and techniques of its administration has been gradually 
improved. It is an alternative for the surgical restoration 
of patency of own artery or vascular bypass, giving in 
certain groups of patients higher benefits than surgery. 
Surgical treatment of acute arterial ischaemia of low-
er limbs has a 30-day mortality index from 15% to 
25% due to complications. Intravascular fibrinolysis is 
a well-tolerated and often used method that can offer 
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few potential advantages in comparison to surgical 
treatment [2].
The significance of the thrombolytic treatment has 
been proven in numerous retrospective trials and in 
carefully designed prospective trials in which individual 
fibrinolytic drugs, their different dosages and the results 
of fibrinolytic treatment and the results of surgical treat-
ments were compared. Skipping the detailed analysis of 
the results of the above-mentioned mentioned trials, 
citation of which exceeds the range of this report, the 
following studies need to be mentioned: STILE, TOPAS, 
PURPOSE, and PARES [3–15].
Applying the targeted thrombolysis in treating 
the arterial and vascular bypass thrombosis can be 
a beneficial alternative for the surgical treatment (in 
the STILE study [11] this thesis was confirmed) and for 
thrombolysis with intravenous infusion of the drug. This 
approach also allows to avoid flaws connected to both 
these methods. Administration of the fibrinolytic drug in 
the direct vicinity or directly into the thrombus allows to 
lower the drug dosage by many times in comparison to 
dosages used in intravenous infusion of the drug, despite 
the used technique of thrombolysis and to shorten the 
treatment duration. The thrombolytic drug dosage size 
is directly connected with the risk of general lytic state 
and haemorrhagic complications [7, 16–19].
The method of restoring arteries patency using the 
balloon catheter proposed by Fogarty in the 1960s 
[20, 21] resulted in improvement of the techniques of 
thrombectomy and embolectomy. Despite this, in next 
years of the observations the attention was drawn also 
to the disadvantages of this method. Due to the throm-
botic changes in the peripheral vessels caused by the 
thrombus, the method can fail to bring the anticipated 
result even with successful restoring patency in the main 
anatomical stem. Furthermore, it can result in damage 
of the endomembrane and provoke development of 
another thrombus in that place. Mechanical deformation 
of the wall and multiple passage of the catheter with an 
expanded balloon can also be the cause of secondary 
extensive stenoses or hyperplastic changes in the ves-
sel’s wall (myointimal hyperplasia) [22–24].
Berridge, Kessel and Robertson et al. analysed five 
controlled trials with 1283 patients that were randomly 
allocated to groups in which peripheral intravascular 
thrombolysis or surgical treatment were used due to 
acute arterial ischaemia of lower limbs. The results, 
however, did not give unambiguous evidences that the 
intravascular thrombolysis or surgical treatment is the 
preferred option in order to avoid amputation of the 
limb or to lower the risk of death in the first year [26]. 
However, local intravascular thrombolysis gave more 
benefits when taking into consideration the costs of 
treatment, duration of hospitalisation and absence, 
and comfort subjectively experienced by the patient 
in comparison to surgical treatment [25].
The aim of the study was an evaluation of the 
effectiveness of the thrombosis of peripheral arteries 
treatment using local intravascular fibrinolysis. 
Material and methods
In 2003–2014, 41 patients with occlusion of lower limb 
arteries in the femoropopliteal section were treated 
with local intravascular fibrinolysis. In 2003–2005 
the studied group comprised of 12 (71%) men and 
5 (29%) women; the average age: 53 years old; the age 
range: 44–75 years. In 2005–2014 the studied group 
comprised of 19 (79%) men and 5 (21%) women, 
the average age: 60 years old; the age range: 42–78 
years. In all cases the occlusion of lower limbs arteries 
concerned the femoropopliteal section. The clinical 
picture of the ischaemia comprised of considerable 
and sudden shortened claudication distance, subjective 
feeling of cold, numbness of resting foot and paleness 
of skin and suppressed filling-in of the surface veins. In 
one patient the thrombosis occurred 12 h after angi-
oplasty and stenting the surface femoral artery. Three 
patients were diagnosed with chronic ischaemia of 
lower limbs in stadium IIb according to the Fontaine’s 
classification and one female patient had no symptoms 
of lower limbs ischaemia in the period preceding the 
occurrence of the arterial thrombus. The risk factors 
of developing sclerosis occurring in the observed group 
were: habitual smoking (30 patients), hypertension 
(18 patients), obesity (7 patients), insulin-dependent 
diabetes (4 patients), and kidney failure (3 patients).
All of the patients had the colour Doppler echo-
cardiography of the arterial flow carried out, and then 
abstract angiography, thanks to which the diagnosis 
had been confirmed. To perform the intravascular 
thrombolysis, 2 types of catheter were used: with one 
axially located hole in 5 cases and with numerous holes 
laterally located in 36 cases. The catheter was inserted 
through the cannula with a valve into the puncture of 
the common femoral artery on the opposite side. The 
tip of the catheter was placed peripherally, just under 
the surface or inside the mass of thrombus.
In 2003–2014 all of the patients received sub-
cutaneous injection of nadroparin in a dosage of 
0.01 mL/kg of body weight or fraxiparine in a dosage of 
1 mg/kg of body weight and then streptokinase (SK) or 
recombined tissue plasminogen activator — alteplase 
(rtPA). Both drugs were administered directly through 
the arterial line, SK in bolus intra-arterially in a dosage 
of 50 000 IU during 30 min, and then constant-rate 
infusion intra-arterially in a dosage of 10 000 IU/h, 
rtPA in bolus intra-arterially in a dosage of 2 mg and 
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then constant-rate infusion intra-arterially in a dosage 
of 0.8 mg/h. The effectiveness of the thrombolysis was 
monitored by arteriography carried out in 1 h since the 
administration of thrombolytic drugs, and then after 
3 h and 6 h of treatment. In the group in which the rtPA 
was used, unfractionated heparin was administered in 
constant-rate infusion intra-arterially in a dosage of 
200 IU/h during 48–72 h after the end of the infusion of 
the thrombolytic drug. In the group, in which SK was 
used, after restoring full patency of artery confirmed by 
angiography, the infusion of thrombolytic was contin-
ued for the next 6 h. During next 48 h unfractionated 
heparin was administered in constant-rate intravenous 
infusion in a dosage allowing 2–3 times increase of 
the activated partial thromboplastin time, and then 
nadroparin in daily subcutaneous dosage of 0.02 mL/kg 
of body weight, fraxiparine in daily subcutaneous dos-
age of 1 mg/kg of body weight or oral anticoagulant in 
therapeutic dosage under the control of the INR index. 
The total treatment time with SK and rtPA was from 
12 to 36 h. Patients were discharged from the unit in 
2 or 3 day after termination of the intravenous treat-
ment with heparin with recommendation to continue 
the subcutaneous injections of nadroparin/fraxiparine or 
oral anticoagulant under the control of the INR index.
Results
Dissolving the thrombus and restoring the arterial flow 
was reached in 15 (88%) from 17 patients in 2003–2005 
(study group treated with SK) and 21 (87.5%) from 
24 patients (group treated with rtPA). In 4 cases the 
local thrombolysis failed and the arterial flow was re-
stored with the Fogarty’s catheter. In the study group 
treated with rtPA two cases of death were noted due 
to acute coronary syndrome and hypertensive crisis. 
Among other patients no haemorrhagic complications 
or deterioration of the blood flow in the treated limbs 
requiring conversion to surgical treatment were found. 
In the group of 7 patients periarterial haematomas in the 
pace of cannulation of the artery that did not require 
surgical intervention were noted. In a patient with 
a thrombus in the stent inserted 2 weeks earlier, after 
restoring patency of the artery, no changes requiring 
additional intravascular surgeries were found. In 8 cases 
serious hemodynamic stenosis was diagnosed and simul-
taneously transcutaneous angioplasty with stenting of 
the narrowed section was carried out. Those patients 
were administered nadroparin/fraxiparine for 10 days, 
and then antiplatelet drugs. One female patient who 
was diagnosed with 40% stenosis of popliteal artery 
did not express consent to proposed angioplasty and 
stenting. After the end of injections of the nadroparin 
she started to use oral anticoagulants. In all of the treat-
ed patients full remission of limb ischaemia symptoms 
was observed.
Discussion
The mechanism of action of the thrombolytic drugs re-
lies on dissolving the fibre contributing to the thrombus 
by activating the inactive plasminogen connected with 
the fibre and creation of the plasmin. Currently, 4 basic 
substances showing fibrinolytic activity are being used, 
however, the use of rtPA predominates:
 — streptokinase (SK) — a substance produced by the 
beta-hemolytic streptococci; SK binds with the cir-
culating fibrinogen in an active complex that causes 
transformation of free plasminogen into a plasmin. 
In patients who suffered streptococcal infection or 
were previously treated with the streptokinase, 
antibodies can be created responsible for the oc-
currence of the anaphylactic reaction or neutralising 
the streptokinase therapeutical action;
 — urokinase (UK) — serine protease; it is produced from 
the foetal kidney cells through genetic recombination. 
Its fibrinolytic activity comprises of direct transforma-
tion of the plasminogen to plasmin. It is considered 
a faster and more effective drug than streptokinase, 
and its antigenic properties are very low;
 — tissue plasminogen activator (tPA) — is produced by 
the vascular endothelium or in laboratory, through 
the genetic recombination. When created in natural 
conditions in the wall of the vessel it results in nor-
mal endothelium having no thrombogenic proper-
ties. In comparison to streptokinase and urokinase 
tPA has significantly higher affinity and specificity 
to fibrin and this result in significantly lower risk of 
generalised haemorrhagic complications.
Other drugs, such as: reteplase (rPA), recombinant 
urokinase (rUK), recombinant prourokinase (r-ProUK), 
recombinant staphylokinase, APSAC are still in the 
stage of clinical trials and are not used in treatments or 
their practical importance is still low [27, 28]. Plasmin 
is a substance that has direct thrombolytic effect with 
extended safety margin shown in the preclinical trials. 
In these trials it was shown that when administering 
the plasmin through intravascular catheter we receive 
effective thrombolysis without adverse symptoms that 
can be observed using the rtPA. The safety of using the 
plasmin is a result of its fast neutralisation with the alpha 
2-antiplasmin that prevents filtering of the plasmin to 
the circulatory system after the end of local thrombo-
lysis. Further studies should evaluate the safety of using 
the plasmin in comparison to rtPA [29–32].
The results of the therapy are by far dependent on 
the qualification of patients to targeted thrombolysis. 
Commonly recognised indications to fibrinolytic treat-
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ments are: acute arterial thrombosis, acute vascular 
bypass thrombosis, chronic artery or vascular bypass 
occlusion lasting no longer than 14 days. Braithwaite 
et al. [33] consider that patients with the symptoms 
lasting no longer than 14 days should be qualified to 
surgical treatment. However, if this procedure would be 
contraindicated the attempt of performing thrombolysis 
can be taken. The results of the therapy in this group 
are significantly lower.
Absolute contraindications to thrombolysis are: 
active bleeding, active stomach and duodenum ulcers, 
stroke < 3 months, surgery or biopsy of parenchy-
matous organ < 2 weeks, cerebral vascular event 
< 6 weeks, metastasis to the central nervous system, 
and lumbar puncture or spinal anaesthesia < 3 days. 
Relative contraindications: suffered bleeding from the 
alimentary tract, surgery, biopsy or extensive injury 
during 10 preceding days, improperly controlled and 
high hypertension, presence of thrombus in the heart 
cavities, pregnancy, impairments of coagulation, acute 
liver failure and portal hypertension. Some authors 
suggest that special caution needs to be taken when 
qualifying the patients with engrafted vascular pros-
thesis, especially in the retroperitoneal space due to 
the possibility of causing a leakage. This observation 
concerns knitted dacron prostheses as well as the 
PTFE prostheses [33–35]. Usage of the streptokinase 
in the past is a contraindication for its second usage. 
This does not concern other thrombolytic drugs. 
Relative contraindications were vaguely determined. 
The attempts of treating patients with the necrosis of 
distal end of limb odd to be considered pointless and 
depreciative of the method, however, in some patients 
this procedure might allow to lower the level of ampu-
tation and to create better conditions for healing the 
stump wound. The decision on performing the therapy 
has to be individualised, and anticipated benefits has to 
significantly exceed the potential and conscious risk.
The final decision on starting the thrombolytic 
treatment has to be at all times preceded by diagnostic 
arteriography with careful exposure of the blocked part 
of the vessel and the vessels located above and below 
its location. This has crucial meaning to monitor the 
progress of the thrombolysis, and when the necessity 
of changing the treatment occurs, to precisely plan the 
surgical procedure.
Several techniques of intra-arterially administra-
tion of the thrombolytic drugs have been developed. 
None of them have become the obligatory standard 
procedure. In his pioneer report on the new method, 
Dotter [1] presented results obtained on the group of 
17 patients, heterogeneous in regards to indications 
to thrombolysis and to used dosage and the way of its 
administration. This group consisted of patients with 
primary thrombosis of own artery, secondary throm-
bosis complicating the intravascular operations, vein 
thrombosis associated to the artery thrombosis, arterial 
embolism. The observation included patients not only 
with the atherosclerosis but also with the Raynaud’s 
disease and embolism caused by the injection of a drug. 
The duration of symptoms was diverse, from a few 
minutes to 4 weeks and more. Dotter applied strep-
tokinase to patients in constant-rate infusion through 
catheter with one hole or with several side openings, 
placed above the thrombus or introduced into the 
thrombus mass. The size of dosage was 2500–10 000 
units per hour.
In 1989 Berridge et al. [17] performed a number of 
reviews of results of 19 prospective trials carried out 
in 1974–1988, in which intra-arterial thrombolysis was 
performed using small dosages of streptokinase (usually 
5000 units/h) or rtPA administered in constant-rate 
infusion. In the conclusions, authors confirmed the 
therapeutic effectiveness of small dosages of locally 
administered thrombolytics in comparison to using 
high dosages that are used in the case of intravenous 
administration of the drug with time lower incidence of 
strokes and haemorrhagic complications at the same. 
Risius et al. [14] compared using two dosages of rtPA 
in the constant-rate infusion intra-arterially. Applying 
a dosage of 0.1 mg/kg/h and 0.05 mg/kg/h in two groups, 
respectively, identical effectiveness of the treatment 
was obtained with significantly lower incidence of 
haemorrhagic complications in the group of patients 
treated with the lower dosage.
The differences in various techniques of throm-
bolysis concerns the used catheter type, their number 
and placement in relation to the thrombus. In 1992 
Hicks [36] performed a review of available systems 
for intra-arterial infusions and shown their clinical 
applications. Catheters with one apical hole or with 
multiple-hole tip are used. Two catheters placed co-
axially are used. The tip of the catheter can be placed 
just above the thrombus or in the thrombus in its whole 
length or it can be moved along with the progress of 
the thrombolysis. The infusion of the drug can be with 
constant rate, preceded by initial bolus or can carried 
out as individual injections or by pulse-spray injections 
into the thrombus (pulse-spray pharmacomechanical 
thrombolysis).
McNamara and Fisher [12] treated patients with 
high dosages of urokinase in constant-rate infusion 
through catheter placed in the thrombus, firstly at 
4000 units/min and after obtaining partial patency 2000 
or 1000 units/min. Similar dosage in constant-rate infu-
sion was used by Sullivan et al. [16] but it was preceded 
by additional infusion of bolus administered directly to 
the thrombus. The results were compared in two groups 
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of patients. In one bolus in low dosage 7000–100 000 
units (on average 52 000 units); and in the second one 
in high dosage 120 000–250 000 units (on average, 
230 000 units) was used. The conclusions in both 
researches were similar. The authors concluded that 
administering high dosages of thrombolytic decreases 
the duration of the thrombus lysis and lowers the total 
dosage of drug necessary to achieve that, and lowers 
the incidence of complications.
On the other hand, Conrad et al. [42] suggested 
re-surgery with implantation of a new vascular bypass 
instead of applying local thrombolysis among patients 
with the vascular graft thrombosis due to bad short- 
-term results of the treatment.
Marder et al. [43], in phase I of the trial, admin-
istered increasing dosages of plasmin (25–175 mg) 
in a group of 83 patients with acute (below 14 days) 
ischaemia of own arteries or vascular graft of lower 
limbs (scale of symptoms I or IIa). He concluded that 
using plasmin in the above-mentioned cases has good 
safety margin and tolerance for dosages 25–175 mg 
administered locally through the intra-arterial catheter. 
The phase II of the trial studies on the safety of applying, 
and indications to administration of plasmin in dosage 
of 150 mg are being developed [44].
The differences in the approach to the thrombolytic 
treatments consider not only the used catheter type 
and its placement, and dosages of drugs but also the 
method of infusion. In the prospective randomised trial, 
Kandarpa et al. [9] compared the results of treatment 
with constant-rate infusion with individual injections 
of pulse-spray type. They did not show significant 
differences between groups in the evaluation of the 
therapy’s effectiveness, the time needed to obtain 
lysis of the thrombus, incidence of complications, and 
results after 30-day observation. Valji et al., Bookstein 
et al., and Gardiner et al. [37–41] consider the pulse- 
-spray injections technique to be the most effective. 
The manipulation with the catheter tip within the 
thrombus and its mechanical breakage with the force 
of the injected stream results in shortening the duration 
of the treatment and lowers the total dosage of used 
drug, and in lowering the incidence of complications. 
Wissgott et al. [45] performed the PARes study to 
evaluate the safety of applying the local thrombolysis 
using ultrasounds in treating acute thrombosis or em-
bolism of arteries in lower limbs. In the study, acute 
ischaemia (below 14 days) was treated applying local 
thrombolysis with rtPA in a dosage of 1.0 mg/h using 
special EKOS catheter for local thrombolysis with the 
ultrasonic device. The effectiveness index was 100%. 
Full removing of the thrombus was noted in a group of 
22 patients (88%) after about 16.9 hours (range 5–24 h) 
using on average 17 mg (range 5–25 mg) of rtPA. In 
the results of the studies it was concluded that using 
the EKOS catheter for local thrombolysis is efficient 
and effective.
With the intra-arterial infusion of the fibrinolytic 
drug, intravenous administration of heparin is recom-
mended to avoid the appearance of new thrombus 
in the vicinity of the catheter. The dosages are very 
variable. Kandarpa [46], Sullivan et al. [16], and McNa-
mara et al. [12] suggest full therapeutic heparinization 
using intravenous heparin bolus of 5000–7000 units, 
and then constant-rate infusion at 1000–2000 units/h. 
Valji and Bookstein et al. [37, 40] administered hep-
arin according to the above plan or made a solution 
for intra-arterial infusion containing 10 mL of volume 
250 000 units of urokinase and 5000 units of heparin 
with simultaneous start of oral antiplatelet treatment. 
Other authors, e.g. Ouriel [19, 28], suggested to 
administer heparin in sub-therapeutic dosages: bolus 
2000 units, and then infusion 200–500 units/h, while 
others, such as Braithwaite et al. [27], did not admin-
ister heparin to their patients during the thrombolysis 
but only during next 48 h from ending it, administering 
dosages allowing 2–3 times increase of activated partial 
thromboplastin time (APTT).
The decision on terminating the treatment is made 
when: the thrombus is completely dissolved, significant 
haemorrhagic complications occur, the state of the 
limb is deteriorating and there is a necessity of urgent 
performance of a surgery, the anticipated hemodynamic 
effect did not occur during 48 h of treatment. Accord-
ing to Ouriel [28] carrying out the fibrinolysis further 
in those cases can lead to the increase of incidence of 
haemorrhagic complications. From the clinically signi-
ficant deterioration of the limb state, resulting from the 
persistent ischaemia, the passing deterioration of the 
peripheral parts of the limb, especially the foot, caused 
by the distal embolization with not entirely dissolved 
excerpts of thrombus needs to be distinguished. Galland 
et al. [47] consider that maybe it is permanent, but 
not always clinically visible, part of the thrombolytic 
treatment. The peripheral micro-embolization arises 
in a moment when the flow is restored in so far closed 
vessel. Usually small thrombi are dissolved when the 
thrombolytics infusion is continued. It has to be stressed 
that dissolution of the thrombus is the first stage of the 
treatment, and further procedure should aim at deter-
mining and removing the cause of the arterial occlusion. 
Patients who have been diagnosed with the arterial 
stenosis can be qualified for planned surgical treatment 
or to the therapy with transcutaneous endovascular 
techniques, preferably directly after the termination 
of thrombolysis and using the angioaccess created to 
carry out the thrombolysis. If the cause cannot be found 
by angiography, the intravascular ultrasound needs to 
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be carried out. Lack of local cause of the occlusion or 
closing of the vessel caused by thrombus originating 
from higher located parts of the arteries or the heart 
cavities comprise indications to implement the long-
-term anti-coagulative treatment with low molecular 
weight heparin or oral anticoagulants. It can be also ad-
visable to perform diagnostic procedures excluding the 
presence of clinical syndromes with hypercoagulability.
Conclusions
Local intravascular fibrinolysis is a good and effective 
method of treating the ischaemia of lower limbs in 
certain patients. It allows to significantly lower the 
thrombolytic drug dosage in comparison to the intrave-
nous infusion, what leads to decreasing the incidence of 
complications. Careful determination of the indications 
and complying with the contraindications to apply fi-
brinolysis allows to obtain good results thanks to using 
the treatment less affecting the patient in comparison 
to the surgical treatment. Local fibrinolysis allows to 
shorten the hospitalisation and absence due to sickness 
time what is economically beneficial for the patient 
himself as well as for the clinic treating him. 
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